Colon Microbiocenosis and Its Correction in Patients Receiving Programmed Hemodialysis

Area of Science:

• Microbiology and Gastroenterology
• Renal Medicine and Therapeutics

Background:

• Patients with chronic kidney disease (CKD) undergoing programmed hemodialysis often exhibit dysbiosis.
• Dysbiosis in CKD patients is characterized by reduced lacto- and bifidoflora and increased opportunistic pathogens.
• These microbial imbalances are associated with inflammation, azotemia, and a diminished quality of life.

Purpose of the Study:

• To investigate the species composition of colon microbiocenosis in hemodialysis patients.
• To evaluate the efficacy of a novel immobilized synbiotic (LB-complex L) in correcting dysbiosis.

Main Methods:

• Colon microbiota samples were collected from 62 hemodialysis patients before and after synbiotic therapy.
• Microbial identification utilized MALDI-TOF mass spectrometry.
• Efficacy was assessed via clinical data, questionnaires, and bacteriological tests.

Main Results:

• Pre-therapy analysis revealed dysbiosis, inflammation, and azotemia in all patients.
• Post-therapy with LB-complex L, 56% of patients showed normalized microbiocenosis.
• Significant reductions in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were observed, alongside improved quality of life.

Conclusions:

• Dietary supplementation with immobilized synbiotics can restore gut microbiota structure in hemodialysis patients.
• This normalization of gut microbiota leads to improved health outcomes and quality of life.
• Synbiotic therapy represents a promising approach for managing complications associated with CKD and hemodialysis.